Home / Resource Library / Subgroup analysis of older patients >60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Subgroup analysis of older patients >60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Results of a study investigating polatuzumab vedotin for first line treatment of elderly patients with DLBCL.